HIGHLIGHTS
- who: Paola Minetto and collaborators from the Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy have published the article: Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden, in the Journal: (JOURNAL)
- what: With the limitations of a retrospective study, FLAI-5 seems to be an effective therapy for NPM1 mut AML patients, regardless of FLT3-ITD status and may not require the application of HSCT in first CR, especially in patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.